Medical devices, healthcare technology and the business of care
510(k) clearance · K252353

myray ProXIma X6

Cefla S.C. · Decision date Mar 10, 2026

FDA DECISIONK252353

What did the FDA decide?

FDA records K252353 as a 510(k) premarket notification, with a decision dated Mar 10, 2026. The decision code SESE records a finding of substantial equivalence. This is a 510(k) clearance.

Regulatory pathway
510(k) premarket notification
Clinical specialty
Radiology
Decision date
Mar 10, 2026

FDA source record

Regulatory record facts

Identifier
K252353
Regulatory pathway
510(k) premarket notification
Applicant
Cefla S.C.
Product code
OAS
Decision code
SESE
Decision date
Mar 10, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: X-Ray, Tomography, Computed, Dental.

Applicant
Cefla S.C.
Product code
OAS
FDA device class
2

FDA decision timeline

  1. K252353 received

    Application receipt date recorded by FDA.

  2. K252353 · FDA decision

    SESE

Related devices and submissions

Explore the linked device profile

Other records with product code OAS

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Cefla S.C.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Imola (Bo)

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records